about
Mapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis ControlGenetic heterogeneity in Loa loa parasites from southern Cameroon: A preliminary studyDisability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathyOnchocerciasis-related epilepsy? Prospects at a time of uncertaintyGenetic selection of low fertile Onchocerca volvulus by ivermectin treatmentDynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multiply treated population from CameroonReproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-naïve and a frequently treated population from CameroonAnalysis of nematode motion using an improved light-scatter based systemRiver blindness: a success story under threat?Epilepsy in onchocerciasis endemic areas: systematic review and meta-analysis of population-based surveys.Lymphatic vascularisation and involvement of Lyve-1+ macrophages in the human onchocerca nodule.A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia.A case study of risk factors for lymphatic filariasis in the Republic of Congo.The global burden of disease study 2010: interpretation and implications for the neglected tropical diseasesAnalysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.Allergen-specific IgE and IgG4 are markers of resistance and susceptibility in a human intestinal nematode infection.Case-control studies on the relationship between onchocerciasis and epilepsy: systematic review and meta-analysis.Onchocerciasis: the pre-control association between prevalence of palpable nodules and skin microfilariaeEncephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp.Case report: Loiasis with peripheral nerve involvement and spleen lesionsThe impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo.Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope.Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West AfricaMeasurement of Circulating Filarial Antigen Levels in Human Blood with a Point-of-Care Test Strip and a Portable SpectrodensitometerProgress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results.Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis.Semi-quantitative scoring of an immunochromatographic test for circulating filarial antigen.Impact of repeated ivermectin treatments against onchocerciasis on the transmission of loiasis: an entomologic evaluation in central Cameroon.Identifying sub-optimal responses to ivermectin in the treatment of River Blindness.Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment.Positivity of Antigen Tests Used for Diagnosis of Lymphatic Filariasis in Individuals Without Wuchereria bancrofti Infection But with High Loa loa Microfilaremia.Absence of an association between Plasmodium falciparum infection and post-ivermectin Loa-related non-neurologic serious adverse events.
P50
Q24800816-79EBC6B5-28CD-4FB3-9547-2174B905F7CAQ24804532-BC0A0F79-30B4-4B12-9E4C-4C3C7156A881Q27860791-2B7B8D5D-C38C-4B9D-A347-3082490BEC42Q27860879-3F2AD8F5-4E4D-4D56-915B-96A9BB4BB688Q28111913-50659953-F27F-42E4-9500-6C8D464497BBQ28217814-0C8E4EB4-6ED5-423C-A6C5-571D1E0DE3F7Q28283535-AD6777A6-FFE1-4F49-BFCB-1294D4CBBCE9Q28469339-CD5819C7-7F44-486F-9384-02D707E3CD32Q28487094-51ACA0B9-FB0F-431E-90C6-19E71A231BFEQ28538222-8B31FACA-A4B3-45E3-A64A-E48006350145Q28543545-F148640A-9483-4159-AABD-F57AE301BAC1Q33258476-52A12A87-46FF-4A1A-A9B9-F1722C38C837Q33468406-DBF7F2AE-DA91-4B8D-A31D-6DC2602EBF90Q33518439-145B9499-620E-4EA3-8CD5-78683AA2F79CQ33693580-379490E9-224F-4C58-8F8F-07078D920BF9Q33874155-1150B9DE-A9EB-410A-971F-AB6FBDA6D82BQ33945536-69E5EBF7-DC74-439D-A287-D7CCFA37FD99Q34030191-8E9E3FEF-C7F5-4D5F-A1A9-C4E19F690ACFQ34427046-31F43F03-AF87-442F-9990-5C0A60D9075AQ34654304-98B8D008-59BF-4274-847C-EFAACE56230EQ34675134-B85F9A11-7796-4560-B83C-340B29025707Q34767120-8DD8CB8E-9C72-484B-A1F6-DA2DAD71256FQ34875613-A4B81056-FB46-4EAD-B3C5-C5C9F0622400Q35590790-F661E0E1-730A-4145-AC84-F2917D68ADDCQ35623478-3440509F-49CC-40FA-925B-E67BB6392B39Q35895175-20157A81-C16B-4F19-B9D3-5FCE6694CCD0Q36958528-259828A3-A62F-41F9-865D-750EE8512B9DQ37045287-06EFF61E-CF47-495A-A293-B752912C55A0Q37159863-6FA67059-C1C5-4688-B0C9-6649658AEBEDQ37287695-39B7F8D5-700E-42E2-B315-8750AB2273ADQ37362005-C639096B-3D3C-4255-BC0A-6CB500912CB6Q37377289-EC912450-F74D-4F71-B97A-EC36FA5CAC39Q37414564-60E6DB50-F1A7-48AF-BB4A-BCB8F30229CAQ37499515-93F81123-1214-452A-A252-739D24620BBDQ37572997-47BF5FC7-2129-4D7E-8CE6-1F09765962E9
P50
description
onderzoeker
@nl
name
Michel Boussinesq
@ast
Michel Boussinesq
@en
Michel Boussinesq
@es
Michel Boussinesq
@sl
type
label
Michel Boussinesq
@ast
Michel Boussinesq
@en
Michel Boussinesq
@es
Michel Boussinesq
@sl
prefLabel
Michel Boussinesq
@ast
Michel Boussinesq
@en
Michel Boussinesq
@es
Michel Boussinesq
@sl